Figure 2.

AF Incidence Rates by Anticancer Drugs and by Cancer Localization

Summary annualized incidence rates of atrial fibrillation (AF) reporting associated with exposure to 1 of 15 anticancer drugs used as monotherapy in clinical trials per 100 observations by anticancer drugs and by cancer localization with ClinicalTrials.gov studies posted up to September 18, 2020 (no AF event was reported for obinutuzumab, and no study was included for anthracyclines and cisplatin). Placebo refers to the summary annualized incidence rates of AF reporting associated with placebo arms of included trials. The color code provides visual information on the summary annualized incidence rate of AF reporting (yellow, the lowest incidences, followed by gold, orange, red, and then purple, the highest incidences). GIST = gastrointestinal stromal tumor; MDS = myelodysplastic syndrome.